US accuses Regeneron of fraudulent price reporting for eye drug
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
RBC on Regeneron Pharma (REGN):'The Buying Opportunity Many Have Been Looking For, With Overdone DOJ Downside On Top Of Recent Weakness'
April 11, 2024 11:40 AM EDTRBC Capital analyst Brian Abrahams reiterated a Sector Perform rating and $1,189.00 price target on Regeneron Pharma (NASDAQ: REGN)
The analyst comments "We note that DOJ has filed a complaint against REGN, accusing the company of fraudulently inflating Medicare reimbursement rates for Eylea. To our read, this is in regard to REGN's practice in reimbursing credit card transaction fees to distributors that occurred when physicians purchased the product using credit cards. While we do not know what the exact damages would be in case of potential settlement, given the complaint highlighting $250M in... More
